News >

Liquid Biopsy Matches Tissue for NSCLC Treatment Guidance

Published: Thursday, Sep 12, 2019

Hai T. Tran, PharmD

Hai T. Tran, PharmD

Patients with advanced non–small cell lung cancer (NSCLC) and actionable mutations had similar progression-free survival (PFS) whether treatment guidance came from tissue or circulating tumor (ct)DNA analysis using the Guardant360 assay, a matched retrospective comparison showed.

The comparison of targetable mutations identified by ctDNA and tissue in 122 matched cases showed strong agreement between the 2 testing techniques. The overall diagnostic accuracy was 99.6% and was 100% for 8 of 11 types of targetable mutations identified. Sensitivity was 99.2%, specificity 99.7%, PPV 96.7%, and NPV 99.9%.
Tran H, Lam V, Vasquez M, et al. Outcomes in advanced NSCLC patients treated with 1st line EGFR-TKI based on mutation detection from tissue or cfDNA-based genomic sequencing. Presented at: IASLC 20th World Conference on Lung Cancer; September 7-10, 2019; Barcelona, Spain. Abstract P1.01-98.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x